Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients

Biochemical and Biophysical Research Communications

Volumn 435, Issue 3, 2013, Pages 493-500

  Han, Ju ^a   Tian, Rui ^a   Yong, Bicheng ^a   Luo, Canqiao ^a   Tan, Pingxian ^a   Shen, Jingnan ^a   Peng, Tingsheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; AXL; Migration and invasion; Osteosarcoma

Indexed keywords

AXL PROTEIN; GELATINASE B; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CELL INVASION; CELL MIGRATION; CHILD; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84878982950     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.05.019     Document Type: Article

References (23)

1. Gill J., Ahluwalia M.K., Geller D., Gorlick R. New targets and approaches in osteosarcoma. Pharmacol. Ther. 2013, 137(1):89-99.
2. O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., Espinosa R., Le Beau M.M., Earp H.S., Liu E.T. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell Biol. 1991, 11(10):5016-5031.
3. Stitt T.N., Conn G., Gore M., Lai C., Bruno J., Radziejewski C., Mattsson K., Fisher J., Gies D.R., Jones P.F., et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995, 80(4):661-670.
4. Korshunov V.A. Axl-dependent signalling: a clinical update. Clin. Sci. (Lond.) 2012, 122(8):361-368.
5. Collett G.D., Sage A.P., Kirton J.P., Alexander M.Y., Gilmore A.P., Canfield A.E. Axl/ phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ. Res. 2007, 100(4):502-509.
6. Verma A., Warner S.L., Vankayalapati H., Bearss D.J., Sharma S. Targeting Axl and Mer kinases in cancer. Mol. Cancer Ther. 2011, 10(10):1763-1773.
7. Sawabu T., Seno H., Kawashima T., Fukuda A., Uenoyama Y., Kawada M., Kanda N., Sekikawa A., Fukui H., Yanagita M., Yoshibayashi H., Satoh S., Sakai Y., Nakano T., Chiba T. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol. Carcinog. 2007, 46(2):155-164.
8. Shieh Y.S., Lai C.Y., Kao Y.R., Shiah S.G., Chu Y.W., Lee H.S., Wu C.W. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005, 7(12):1058-1064.
9. Song X., Wang H., Logsdon C.D., Rashid A., Fleming J.B., Abbruzzese J.L., Gomez H.F., Evans D.B., Wang H. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011, 117(4):734-743.
10. Rankin E.B., Fuh K.C., Taylor T.E., Krieg A.J., Musser M., Yuan J., Wei K., Kuo C.J., Longacre T.A., Giaccia A.J. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 2010, 70(19):7570-7579.
11. He L., Zhang J., Jiang L., Jin C., Zhao Y., Yang G., Jia L. Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol. Carcinog. 2010, 49(10):882-891.
12. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 2012, 1825(1):29-36.
13. Hafizi S., Dahlbäck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006, 17(4):295-304.
14. Nakano T., Tani M., Ishibashi Y., Kimura K., Park Y.B., Imaizumi N., Tsuda H., Aoyagi K., Sasaki H., Ohwada S., Yokota J. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin. Exp. Metastasis 2003, 20(7):665-674.
15. Messa C., Russo F., Pricci M., Di Leo A. Epidermal growth factor and 17beta-estradiol effects on proliferation of a human gastric cancer cell line (AGS). Scand. J. Gastroenterol. 2000, 35(7):753-758.
16. Shaw R.J., Paez J.G., Curto M., Yaktine A., Pruitt W.M., Saotome I., et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 2001, 1:63-72.
17. Yang M.H., Chang S.Y., Chiou S.H., Liu C.J., Chi C.W., Chen P.M., et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007, 26:1459-1467.
18. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61(22):8118-8121.
19. Linger R.M., Keating A.K., Earp H.S., Graham D.K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 2008, 100:35-83.
20. Wang S.C., Hung M.C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. 2009, 15(21):6484-6489.
21. Ou W.B., Corson J.M., Flynn D.L., Lu W.P., Wise S.C., Bueno R., Sugarbaker D.J., Fletcher J.A. AXL regulates mesothelioma proliferation and invasiveness. Oncogene 2011, 30(14):1643-1652.
22. Papadakis E.S., Cichoń M.A., Vyas J.J., Patel N., Ghali L., Cerio R., Storey A., O'Toole E.A. Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members. J. Invest. Dermatol. 2011, 131(2):509-517.
23. Tai1 K.Y., Shieh Y.S., Lee C.S., Shiah S.G., Wu C.W. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-jB and Brg-1. Oncogene 2008, 27:4044-4055.